Scope
People with prolonged disabling fatigue or an existing ME/CFS diagnosis. NHMRC explicitly states that it has never issued or approved ME/CFS guidance and that no current Australian clinical practice guideline exists; recommendations are still under development for 2027 consultation and 2028 implementation. The only clinical implementation source here is Gold Coast Health鈥檚 March 2026 adult internal-medicine referral criteria, which apply in that Queensland service area.
The Bottom Line
- Do not present the NHMRC development page, scoping work or future timeline as a diagnostic or treatment recommendation; no Australian national ME/CFS CPG is currently available.
- Document onset, duration, progression, activity-related symptom change, cognitive, sleep, orthostatic, pain and functional effects and the degree to which work, education, self-care and travel are limited.
- Investigate alternative explanations from history and examination with targeted tests rather than a repeated indiscriminate panel, and record what has already been excluded before referral.
- Within Gold Coast Health, refer diagnostic uncertainty, substantial functional impairment or persistent unexplained fatigue using the published adult internal-medicine criteria and required clinical information; elsewhere use the local pathway.
- Make uncertainty explicit and use shared symptom and disability support without claiming that pacing, graded activity, supplements or any medicine is endorsed by NHMRC before the national recommendations are published.
Practical clinical workflow
1
Establish whether the problem is new, rapidly progressive or stable and record fever, weight loss, lymphadenopathy, dyspnoea, syncope, focal neurology, sleepiness while driving and other features that change urgency.
2
Perform a focused physical and mental-health assessment, review medicines and substances and choose investigations from the differential and the exact referral information required by the receiving service.
3
Describe function and symptom fluctuation in the person鈥檚 own terms, including delayed worsening after exertion if reported, and adapt appointment length, travel and communication to avoid unnecessary assessment burden.
4
For Gold Coast referrals, include the clinical question, trajectory, examination, prior treatment and response, comorbidity, medicines, functional or cognitive decline and the listed essential investigations; request override when clinical judgement indicates greater urgency.
5
Arrange ownership for new results and deterioration while awaiting review and revisit the evidence boundary when NHMRC publishes consultation or final recommendations rather than allowing this interim page to become permanent guidance.
Safety boundaries and escalation
- Sudden decompensation, serious cardiorespiratory compromise, syncope, focal neurology, significant weight loss, fever, unexplained lymphadenopathy, severe dehydration or suicidality requires urgent alternative-diagnosis assessment.
- Do not attribute every new symptom to ME/CFS or allow a previous label to block evaluation of infection, endocrine, haematological, cardiac, neurological, sleep or medication-related disease.
- Do not describe fixed graded exercise, pacing, dietary supplements or off-label medicine as an Australian national guideline recommendation while NHMRC鈥檚 evidence review and recommendations remain unfinished.
- A long public-specialist wait does not replace clinical monitoring; use the local emergency pathway or a documented clinical override when the person deteriorates.
Implementation
NHMRC鈥檚 absence statement and development timeline are national. The only active clinical pathway linked here is Gold Coast Health adult internal medicine in Queensland, updated 16 March 2026; its categories, required tests and destination do not apply elsewhere. Other clinicians must locate their state, territory or health-service pathway and verify future treatment content against the national recommendations once published.
Clinical use boundary
This independently written summary is not an official guideline. Check the linked source version, current TGA-approved product information where medicines are involved, and the applicable state, territory and local pathway at the point of care.
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- National Health and Medical Research CouncilME/CFS Clinical Practice Guidelines development and scoping reportAustralian guideline under development; draft consultation expected 2027 and publication anticipated 2028 路 accessed 2026-08-20view source
- Gold Coast Health, Queensland GovernmentComplex or undifferentiated medical problems: ME/CFS referral criteria and required clinical informationAdult internal-medicine referral criteria updated 16 March 2026 路 accessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Australia question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.